Sucampo Pharma (SCMP) Misses Q3 EPS by 1c; Boosts FY14 Earnings Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts SCMP Hot Sheet
Price: $18.00 --0%
Financial Fact:
Research and development: 9.98M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Research and development: 9.98M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Sucampo Pharma (NASDAQ: SCMP) reported Q3 EPS of $0.03, $0.01 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $31.5 million versus the consensus estimate of $26.11 million.
Sucampo raised its full year 2014 earnings guidance to $15.0 million to $20.0 million net income, excluding special items, versus previous guidance of $4.0 million to $6.0 million.
For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Clover Health Investments (CLOV) Tops Q3 EPS by 1c ; Offers Guidance
- McKesson (MCK) Tops Q2 EPS by 97c; raises guidance
- AppLovin (APP) Tops Q3 EPS by 26c, Beats on Revenue; Offers Q4 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
